Kornimate/medical-research-clean huggingface dataset:
right ventricular involvement in inferior myocardial infarction patients using 2 dimensional speckle tracking echocardiography

Conditions: Acute Myocardial Infarction of Inferior Wall Involving Right Ventricle (Disorder)

Summary: right ventricular infarction usually occurs in association with inferior myocardial infarction in about 10-50% of the cases. currently the presence of elevation in right pericordial leads is the most powerful indicator of right ventricular infarction. the incidence of right ventricular infarction is more in postmortem studies,meaning that right ventricular infarction is underestimated, possible explanation for this difference could be explained that electrocardiographic sign of right ventricular infarction disappear early or patients presented late.

the incidence of right ventricular infarction is more in postmortem studies,meaning that right ventricular infarction is underestimated, possible explanation for this difference could be explained that electrocardiographic sign of right ventricular infarction disappear early or patients presented late the role of right ventricular systolic function in inferior myocardial infarction patients with or without right ventricular infarction had been studied. in our study we will assess right ventricular infarction in patients of acute inferior myocardial infarction undergoing primary percutaneous coronary intervention by correlating electrocardiogram, right ventricular systolic function by echocardiography with the angiographic finding.

Eligibility criteria:
inclusion criteria: 1. patients of recent acute inferior myocardial infarction. 2. patients managed by primary percutaneous coronary intervention. exclusion criteria: 1. pervious inferior myocardial infarction. 2. inferior myocardial infarction treated by thrombolytic therapy. 3. chronic pulmonary disease. 4. estimatedpulmonary artery systolic pressure ≥35 mmhg by echocardiography. 5. valvular heart disease. 6- dilated cardio-myopathy patients.
cryotherapy on muscle function

Conditions: Cold; Cryotherapy; Cryotherapy Effect; Muscle Activity; EMG

Summary: on-field sports injuries are a common issue that significantly impacts athletes' performance and overall health. in team sports such as football, basketball, and volleyball, muscle and joint injuries are particularly frequent. cryotherapy, including cold pack and cold spray applications, is widely used in the acute management of such injuries due to its practicality and rapid application. it is effective in reducing pain and edema by constricting blood vessels and slowing neural activity. while its analgesic effects are well-known, some studies suggest cryotherapy may also influence balance and proprioception. this study aims to investigate the acute effects of cryotherapy (cold pack and spray) on muscle mechanical properties, muscle strength, pain and emg activity in healthy individuals. a randomized, controlled experimental study will be conducted on healthy participants. subjects will be divided into two groups: cold pack application and cold spray application. quadriceps muscle mechanical properties will be assessed using a myoton device; muscle strength will be evaluated via dynamometry, and muscle activity will be evaluated via electromyographic (emg) device- neurotrac® myoplus 2. each participant will be evaluated at four time points: baseline (pre-intervention), immediately after the intervention, 3 minutes post-intervention, and 5 minutes post-intervention. the effects of each modality will be compared both within and between groups to assess the short-term physiological changes induced by cryotherapy.


Eligibility criteria:
inclusion criteria: * being male * aging 18-25 * having no history of cardiovascular or peripheral vascular disease, diabetes mellitus, neuromuscular pathology, peripheral neuropathy, lower extremity pain, or previous lower extremity surgery * being volunteer exclusion criteria: * having a history of insensitivity to local heat or cold

Keywords: cryotherapy muscle activity
the effect of cocoa flavonoids on blood pressure

Conditions: Hypertension

Summary: the purpose of this study is to compare the effects on blood pressure of a daily intake of a flavonoid-rich cocoa drink with that of the same drink from which the flavonoids have been largely extracted.

flavonoids are natural substances found in fruits and vegetables, tea and red wine. the investigators know that people who eat a diet rich in these foods are less likely to have heart disease. this, in part, may be due to the blood pressure lowering effect of flavonoids. cocoa beans are a rich natural source of flavonoids. unfortunately when cocoa is made into chocolate most of the flavonoids are destroyed. the aim of this study is to find out the effect of cocoa flavonoids on blood pressure after 12 weeks of daily consumption of a specially prepared chocolate drink that is rich in flavonoids.

Eligibility criteria:
inclusion criteria: * males or females of any age. * diagnosis of hypertension and on antihypertensive treatment. * stable blood pressure that has reached the british hypertension society (bhs) audit standard (\<150/90mmhg). exclusion criteria: * participation in another clinical trial. * any reason to suspect that the patient will not comply with drinking a chocolate beverage every day for the trial duration.

Keywords: randomised double blind trial blood pressure cocoa flavonoids
flexible reaching control in parkinson disease

Conditions: Parkinson Disease

Summary: current research and theories have highlighted that the parameters linked to movement planning, e.g. the decision to select a movement goal, and adaptation, e.g. the ability to update control dependent on a novel dynamical context, are update quickly and within an ongoing movement in the general population. in parallel, it has been suggested that the evaluation of movement costs is a function of the basal ganglia, and it is impaired in parkinson disease (pd). here the investigators want to test whether these mechanisms also alter the ability of patients to update control during an ongoing action. a positive result would confirm that movement-related costs and dynamical representations depend on the integrity of the basal ganglia, in contrast a negative result would indicate that the deficit in pd is more specifically related to movement initiation, which would invite one to reconsider the cause of bradykinesia in this population.


Eligibility criteria:
inclusion criteria: * ability to perform the task (assessed during the experiment) exclusion criteria: * inability to perform the task (motor) or to understand the task requirements (cognitive)
ultrasound treatment of rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the research objective of the pilot study is to assess early feasibility of safety and efficacy of spleen ultrasound stimulation in the treatment of rheumatoid arthritis (ra) in a blinded and randomized controlled trial. specific aims include: * measure ra disease activity and functional/biomarker metrics during and after a 2- week course of spleen-directed daily ultrasound treatments (within-arm and between-arm assessments); and * monitor adverse events during and after daily ultrasound treatments.


Eligibility criteria:
inclusion criteria: 1. males and females aged 18 and over. 2. must carry a diagnosis of rheumatoid arthritis, as defined by the american college of rheumatology in 2010: (https://www.rheumatology.org/portals/0/files/2010_revised_criteria_classification_ra.pdf). classification as "definite ra" is based on the confirmed presence of synovitis in at least one joint, absence of an alternative diagnosis that better explains the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in 4 domains: number and site of involved joints (score range 0-5), serologic abnormality (score range 0-3), elevated acute-phase response (score range 0-1), and symptom duration (2 levels; range 0-1). 3. exhibiting symptoms or signs of inadequate disease control according to one of 2 measures: modified haq score of greater than 0.3 and das28-crp greater than 3.2 (http://www.phusewiki.org/wiki/index.php?title=disease_activity_score_-_crp_(das-crp). 4. participants should have home access to broadband internet, such that online video conversations can occur with study personnel via study-provided personal digital assistive devices. exclusion criteria: 1. active bacterial or viral infection. 2. pregnant women or presence of active malignancy. 3. inability to perform minimal daily self-cares associated with feeding/dressing, according to haq.
hepcidin in anemic chronic heart failure (chf) patients

Conditions: Anemia; Chronic Heart Failure

Summary: background: anemia in chronic heart failure (chf) is directly linked to increased mortality and reduced exercise capacity. the pathomechanism for the development of anemia in chf is not well understood. impairment of iron homeostasis is discussed to be one of the major triggers in anemia of chronic disease. hepcidin was recently described as the central regulator of iron homeostasis. main hypothesis: plasma hepcidin levels are altered in anemic chf patients compared to non anemic controls and might be a main contributing factor of anemia in chf. iron regulator-hypothesis high levels of cytokines in chf patients cause up-regulation of hepcidin, which in turn leads to low iron uptake causing anemia. in this case venous hepcidin and hemoglobin concentrations should both correlate with cytokine levels. erythropoietin regulator-hypothesis dysregulation of the erythropoietin system results in anemia, which represses hepcidin. this leads to a negative correlation between hemoglobin and hepcidin in plasma. methods: 100 consecutive patients diagnosed with systolic chf will be prospectively included in the study. iron status will be assessed and hepcidin, erythropoietin as well as interleukin-1, interleukin-6 and soluble tnf alpha receptor levels will be measured by elisa. patients will be followed up for one year and mortality, rehospitalization and worsening of chf will be documented.


Eligibility criteria:
inclusion criteria: 1. systolic left ventricular dysfunction (lvef\<45%) 2. signed informed consent exclusion criteria: 1. women of child bearing potential 2. pregnancy 3. non cardiac illness limiting life expectancy to \<1 year 4. renal disease of non-cardiac reason 5. malignancy 6. chronic inflammatory disease 7. acute infection 8. erythropoietin therapy or iron substitution within the last 6 months
effects of cox-ii inhibitor on biochemical markers in cardiovascular-related adverse effects

Conditions: Arthritis

Summary: the selective cyclooxygenase-2 (cox-2) inhibitors have been associated with increased cardiovascular risk. the goal of the present study is to investigate the impacts of cox-2 inhibitors on biochemical indices in cardiovascular disease. as the reviewer suggested, the investigators propose to study the effects of cox-ii inhibitor using experimentally induced hyperlipidemic rats. plasma total cholesterol, ldl and triglyceride concentrations will be determined before and after animals treated with cyclooxygenase-2 (cox-2) inhibitors. biochemical markers related to cardiovascular events including prostaglandin i2, thromboxanea2 and others will also be investigated. the investigators will also investigate these biochemical markers in patients taking celecoxib and nsaids. the investigators hope these studies will reveal clinically useful biochemical markers for cardiovascular events in patients taking cox-ii inhibitor.


Eligibility criteria:
inclusion criteria: * male/female age \>18 * clinical diagnosed of arthritis exclusion criteria: * must not be pregnant/breastfeeding * other conditions may lead to exclusion from the trial (e.g. diabetes mellitus, malignant melanoma, cardiac conduction disorders, hepatic/renal insufficiency.
a study to gather information about rivaroxaban in patients in the united kingdom who have cancer and thrombosis (oscar-uk)

Conditions: Treatment of Venous Thromboembolism in Cancer Patients

Summary: patients with cancer are more likely than those without cancer to develop blood clots (deep vein thrombosis and pulmonary embolism), which are treated using blood thinners (anticoagulants). when clots occur, cancer patients carry a higher risk of recurring clots and more likely to bleed on blood thinning treatments. therefore, it is critical to use blood thinners that optimize the safety and benefits. there are two main types of blood thinners that are recommended. the tablets which are direct-acting oral anticoagulants and the injections (low molecular-weight heparin). clinical trials show the tablets may reduce clot risk but may potentially lead to more frequent bleeding, particularly in those with certain risk factors such as stomach ulcers, previous bleeding problems, certain cancer type. we aim to examine the effectiveness and safety of the tablets versus the injections for treatment of clots in cancer patients, to better understand these treatments' benefits and risks.


Eligibility criteria:
inclusion criteria: * be ≥18 years of age at the time of anticoagulation initiation * have active cancer and acute deep vein thrombosis (dvt) and/or pulmonary embolism (pe) * treated with rivaroxaban (or any doac) or lmwh as their first recorded anticoagulant prescription 7 to 30 days post-acute cat event diagnosis * have been active in the data set for at least 12-months prior to the index event and had at least one provider visit in the 12-months prior to the acute vte event exclusion criteria: * evidence of atrial fibrillation, recent hip/knee replacement (with 90 days of cat), ongoing vte treatment, valvular heart disease defined as any rheumatic heart disease, mitral stenosis or mitral valve repair/replacement * history of inferior vena cava filter before cohort entry * vitamin k antagonist (vka) use between cohort entry and index day (initiation of doac or lmwh) * evidence of any type of therapeutic anticoagulation use during all available look-back period per written prescription or patient self-report * initiation of rivaroxaban or other doacs or lmwh during the study period at non-therapeutic doses (e.g., enoxaparin at a dose other than 1 mg/kg twice daily or 1.5 mg/kg once daily; dalteparin at a dose other than 200 iu/kg of total body weight) * pregnancy * recording indicative of palliative care before cohort entry * any clinically-relevant bleeding-related d hospitalization or vte recurrence between the initial cat and the start of observation
a pilot randomized controlled trial of intravenous n-acetyl cysteine in stemi

Conditions: STEMI

Summary: the panacea trial is an investigator-initiated prospective, single-center, two-arm, non-blinded pilot randomized controlled trial of high-dose iv n-acetylcysteine therapy used as an adjunct to pharmaco-invasive reperfusion in patients presenting early after a large stemi.

patients presenting with st-segment elevation myocardial infarction within 3 hours of symptom onset and satisfying all of the inclusion criteria after informed consent would be randomly allocated to either intravenous n-acetylcysteine or standard treatment using a 1:1 allocation ratio. those randomized to iv n-acetylcysteine would be administered a bolus of 1200 mg over 0.5 hours (in 5% dextrose) followed by 600mg/hour for the remaining 47.5 hours (in 5% dextrose). a total n-acetylcysteine dose of 29.7 grams is administered over 48 hours. the infusion is continued during the primary percutaneous coronary intervention. patients would be followed up for a minimum of 90 days. the primary clinical endpoint will be myocardial infarct size measured by late gadolinium enhancement cmr imaging at 3-5 days from first medical contact. primary feasibility outcome will be the rate of recruitment, the number of patients undergoing cardiac mri within the stipulated time frame, and completeness of the study data collection.

Eligibility criteria:
inclusion criteria: patients presenting with stemi within 3 hours of symptom onset and satisfying all of the following criteria: 1. patient age ≥ 18 years 2. have received thrombolysis, with intend to pursue a pharmaco-invasive reperfusion strategy. onset of chest pain to reperfusion time of \< 3hrs. 3. stemi involving anterior and/or inferior wall 4. an absence of baseline q-waves on the initial ecg: the presence of q waves defined at baseline using the selvester qrs screening criteria 5. have a high-risk stemi ecg defined as: * ≥2mm st-segment elevation in 2 anterior or lateral leads; or * ≥2 mm st-segment elevation in 2 inferior leads coupled with st-segment depression in 2 contiguous anterior leads for a total st-segment deviation of ≥4 mm exclusion criteria: 1. previous myocardial infarction 2. known to have moderate to severe lv systolic dysfunction (lv ef\< 45%) 3. known allergy to thrombolytic therapy or nac 4. presence of left bundle branch block 5. cardiogenic shock (defined as systolic blood pressure of \< 90mm hg, for at least 30 minutes, not responsive to fluid resuscitation) 6. permanent pacemaker or cardioverter defibrillator implanted previously 7. patients with contra-indications to thrombolytic therapy 8. patients with loss of consciousness or confusion 9. patients with known chronic kidney disease (gfr \< 30ml/min/m2) or on dialysis 10. current pregnancy 11. planned therapy with primary pci

Keywords: stemi
observational study to assess the correlation of edss with quality of life in ms participants treated with natalizumab

Conditions: Multiple Sclerosis

Summary: the primary objective of the study is to determine the association between prospectively measured disability (expanded disability status scale \[edss\]) with quality of life (multiple sclerosis international quality of life questionnaire \[musiqol\]) at 3-month intervals up to 1 year in a real life setting of multiple sclerosis (ms) patients treated with natalizumab. the secondary objectives of this study are as follows: to evaluate the cumulative probability of sustained edss changes at 1 year following natalizumab treatment initiation; to evaluate the association between disability (edss), fatigue (fatigue scale of motor and cognitive function \[fsmc\]), sexual dysfunction (multiple sclerosis intimacy and sexuality questionnaire-19 \[msisq-19\]), depression (beck depression inventory-fast screen \[bdi-fs\]) and neurocognitive function (symbol digit modalities test \[sdmt\]) with euroqol-5d questionnaire (eq-5d) at 3 to 6-months intervals up to 1 year after initiation of natalizumab treatment; to assess the relationship between clinical disease-free status (no edss increase of 1.0 and no relapse) and musiqol at 1 year following natalizumab treatment initiation; to record the number of clinical relapses and relapses requiring steroid treatment at 3-months intervals up to 1 year after initiation of natalizumab treatment; to describe changes in work impairment (work productivity and activity impairment in ms \[wpai-ms\]) at 3-months intervals up to 1 year after initiation of natalizumab treatment; to describe any change in the percentage of disability pension and occupation after 1 year of natalizumab treatment; to record the incidence and number of serious adverse events (sae) and suspected unexpected serious adverse reactions (susar) throughout the study


Eligibility criteria:
key inclusion criteria: * subjects that have a confirmed diagnosis of rrms, as per the 2010 revised mcdonald criteria * subjects satisfying the therapeutic indication of natalizumab, as described in the local product label and confirmed by the investigator. (patients with previous treatment with natalizumab are also considered to be eligible only if the last natalizumab infusion was at least 1 year before the screening visit of this study) * decision for a treatment with natalizumab has been made before screening * patients with an edss score of 2.0-5.5 (both limits inclusive) key exclusion criteria: * patients with a diagnosed co-existing brain pathology other than ms, which in the judgement of the investigator impacts the value of edss or qol. * pure spinal manifestation of demyelination * diagnosis of primary or secondary progressive ms * any change in concomitant medication known to affect cognition or bladder function * a history of severe depressive disorder and/or suicidality, seizure, drug or alcohol abuse, as assessed by the investigator note: other protocol defined inclusion/ exclusion criteria may apply.
clinical trial to compare the efficacy of celiprolol to placebo in patients with vascular ehlers-danlos syndrome

Conditions: Vascular Ehlers-Danlos Syndrome

Summary: this is a prospective, phase 3, randomized, double-blind, placebo-controlled efficacy study to evaluate celiprolol in patients genetically confirmed as col3a1-positive veds using a decentralized clinical trial design.

this is a prospective, phase 3, randomized, double-blind, placebo-controlled efficacy study to evaluate celiprolol in patients genetically confirmed as col3a1-positive veds using a decentralized clinical trial design. the double-blind portion of this study is intended to end if statistical significance is reached at the interim analysis (accrual of 28 veds-related events requiring medical attention; estimated to take 24 months) or after accrual of 46 veds related clinical events requiring medical attention (estimated to take 40 months). a total of approximately 150 patients who meet all the inclusion and none of the exclusion criteria will be enrolled and randomized 2:1 to receive either celiprolol or placebo, respectively. following the double-blind treatment period or occurrence of veds-related clinical event, patients have the option to participate in an open label extension period.

Eligibility criteria:
inclusion criteria: 1. willingness to obtain magnetic resonance angiogram (mra) image at local imaging facility. 2. a genetic test confirming the presence of a pathogenic col3a1 variant (classified as likely pathogenic or pathogenic according to acmg/amp guidelines. 3. patients must be ≥ 15 years of age at the time of randomization. 4. able and willing to discontinue use of β-blockers prior to randomization. exclusion criteria: 1. lack of a col3a1-positive test at screening (e.g., col3a1 benign, likely benign, variant of unknown significance \[vus\] or no variant) or presence of a col3a1 variant but demonstration of a col3a1 variant reported to be a haploinsufficiency variant. 2. arterial rupture or dissection, uterine rupture, and/or intestinal rupture within 6 months prior to screening. 3. patients unable to discontinue β-blocker treatment prior to randomization. 4. unable or unwilling to complete the study procedures. 5. breastfeeding, pregnancy, or planned pregnancy during the trial. 6. any medical condition that in the opinion of the investigator may pose a safety risk to the patient in this study, which may confound efficacy or safety assessment, or may interfere with study participation. 7. use of any prohibited medications